Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD. as Chief Executive Officer
Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs, is pleased to announce the confirmation of Christer Nordstedt MD.PhD. as Chief Executive Officer (CEO). Christer Nordstedt will assume the position on 1st December 2022
GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ -- Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs, is pleased to announce the confirmation of Christer Nordstedt MD.PhD. as Chief Executive Officer (CEO). Christer Nordstedt will assume the position on 1st December 2022.
Christer Nordstedt has abroad and extensive international experience within the pharmaceutical industry from operational and strategic positions at management level in companies like Vivesto, Teva Pharmaceuticals, Orion Corporation, Eli Lilly, Roche, AstraZeneca among others. During his career, Christer has been responsible for large global research projects and leadership in both management, executive, and board roles.
Christer's latest position was interim Chief Executive Officer (CEO) for Vivesto, a pharmaceutical manufacturing company, Uppsala, Sweden. Christer holds a MD and PhD degrees in Pharmacology and Biochemistry from Karolinska Institutet, Sweden. His insights include discovery and clinical development work in neurodegeneration, pain, oncology, and psychiatry.
The Board conducted a rigorous selection process from a group of highly qualified, diverse, and exceptional candidates. This has resulted in the selection of an external candidate, Christer Nordstedt, with a detailed understanding of the biotechnology market and Oblique Therapeutics AB's strategic issues. We welcome Christer Nordstedt to us, and we look forward to running our programs together all the way to the clinic. With Christer's solid experience, we create good conditions and a continuity in the business that makes it easier for us to reach the next level. Christer will be able to provide continuity of purpose of Oblique Therapeutics AB (publ.) with a strong leadership to support the company in its ambitions. We look forward with confidence to working with Christer as the new CEO.
